Dr. Ryan on the Long Term Safety of Abiraterone Use

Charles J. Ryan, MD
Published: Friday, Feb 27, 2015



Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

The safety profile of abiraterone did not change much in subsequent analyses of COU-AA-302, Ryan says. The main adverse events associated with the agent were related to fluid retention, though there was potential for hypokalemia and liver dysfunction.

It was previously demonstrated that adverse events associated with corticosteroid use can be of concern in patients who remain on abiraterone. However, Ryan says, significant corticosteroid toxicities, such as osteoporotic fractures, were not any worse than what would be seen in the general population of patients.

<<< View more from the 2015 GU Cancer Symposium



Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

The safety profile of abiraterone did not change much in subsequent analyses of COU-AA-302, Ryan says. The main adverse events associated with the agent were related to fluid retention, though there was potential for hypokalemia and liver dysfunction.

It was previously demonstrated that adverse events associated with corticosteroid use can be of concern in patients who remain on abiraterone. However, Ryan says, significant corticosteroid toxicities, such as osteoporotic fractures, were not any worse than what would be seen in the general population of patients.

<<< View more from the 2015 GU Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x